remote patient monitoring, cardiovascular biomarkers, and mitra devices
The California Initiative for the Advancement of Precision Medicine (CIAPM) is a national public entity formulated to ignite rational precision medicine research on popular diseases. It recently funded a study that will apply microsampling techniques. The upcoming multi-method, longitudinal, prospective cohort study will engage 200 patients with stable ischemic heart disease (IHD).
Lifestyle choices such as smoking, poor nutrition, and physical inactivity increase the risk of IHD. This disease is the leading killer in the United States in men and women of all ethnicities. For those already diagnosed with the condition, secondary prevention is managed within clinical environments. It focuses on the control of cholesterol, blood pressure, and diabetes.
The risk calculator for atherosclerosis cardiovascular disease is one of the cardiovascular events prediction algorithmic tools. It considers factors such as race, sex, age, blood cholesterol and pressure, smoking status, and diabetes. Such tests are only performed during hospital or clinic visits. The tests help to prevent disastrous situations, improve healthcare access, and lower resource utilization.
The objectives of the upcoming Prediction, Risk, and Evaluation of Major Adverse Cardiac Events (PRE-MACE) study include:
- Estimating the cross-sectional links between the recognized main adverse cardiovascular occurrence (MACE) intermediate biomarkers
- Discovering the longitudinal capability of remote physiological and biochemical monitoring to forecast changes in MACE intermediate biomarkers
- Determining remote monitoring’s and biomarkers’ ability to forecast incident MACE at starting point and after 12 months
- Conducting exploration proteomics and lipidomics aimed at increasing the potential circulating prognostic MACE biomarkers
- Measuring the cost-effectiveness or budget-friendliness of remote monitoring for latent MACE biomarkers and MACE itself
The PRE-MACE learning is aimed at evaluating feasibility regarding adherence and pilot remote monitoring with biosensors, and biomarkers. The study will actively use patient-reported outcomes (PROs) to obtain continuous insight of participants in real-time situations.
The study will rely on Neoteryx’s Mitra® Microsampling device for remote biochemical biomarker monitoring. The FDA-listed class 1 mechanism enhances remote, longitudinal, and volumetric blood sample collection via simple finger pricks.
The Mitra® device has an absorbent polymeric tip that uptakes blood by a fixed volume (10 µL). This enhances sample heterogeneity and overcomes hematocrit bias challenges common with dried blood spots. The study will use automated email reminders or push notifications to remind participants to make their scheduled draws.
This study is just one of the numerous smarter healthcare practices being advanced by clinicians worldwide. Microsampling technology allows for volunteers to participate in clinical trials for longer periods. It makes the studies more flexible and convenient for both the clinicians and the volunteers. Microsampling could be just what your research needs to get to the next level.